Product
Rivoceranib
5 clinical trials
6 indications
Indication
Hepatocellular CarcinomaIndication
Adenoid Cystic CarcinomaIndication
Olfactory NeuroblastomaIndication
Recurrent Olfactory NeuroblastomaIndication
Thymic Epithelial TumorIndication
Colorectal CancerClinical trial
A Randomized, Open-Label, Multi-Center, Phase Ⅲ Clinical Study of Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or AblationStatus: Active (not recruiting), Estimated PCD: 2024-07-31
Clinical trial
A Phase 2 Open-Label, Multicenter, Study to Evaluate the Efficacy and Safety of Rivoceranib in Subjects With Recurrent or Metastatic Adenoid Cystic Carcinoma of All Anatomic Sites of OriginStatus: Completed, Estimated PCD: 2023-06-28
Clinical trial
A Phase II Study of Rivoceranib for Patients With Recurrent or Metastatic Olfactory NeuroblastomaStatus: Not yet recruiting, Estimated PCD: 2026-11-30
Clinical trial
A Phase II, Open-label, Single-arm, Multi-center Clinical Trial of Rivoceranib in Patients With Metastatic Thymic Epithelial TumorStatus: Not yet recruiting, Estimated PCD: 2026-03-01
Clinical trial
Phase 1b/2 Open-label Study to Evaluate the Safety, Tolerability and Efficacy of Rivoceranib or Trifluridine/Tipiracil as Monotherapies and Rivoceranib and Trifluridine/Tipiracil as Combination Therapy in Subjects With Metastatic Colorectal CancerStatus: Terminated, Estimated PCD: 2023-05-31